These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11850206)

  • 1. Aromatase and COX-2 expression in human breast cancers.
    Brodie AM; Lu Q; Long BJ; Fulton A; Chen T; Macpherson N; DeJong PC; Blankenstein MA; Nortier JW; Slee PH; van de Ven J; van Gorp JM; Elbers JR; Schipper ME; Blijham GH; Thijssen JH
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):41-7. PubMed ID: 11850206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH; Jelovac D; Long B
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
    Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT
    BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
    Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM
    J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors and their antitumor effects in model systems.
    Brodie A; Lu Q; Liu Y; Long B
    Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral aromatase model: the effects of letrozole (CGS 20267).
    Brodie A; Lu Q; Yue W; Wang J; Liu Y
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S23-6; discussion S33-7. PubMed ID: 9797014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention strategies with aromatase inhibitors.
    Goss PE; Strasser-Weippl K
    Clin Cancer Res; 2004 Jan; 10(1 Pt 2):372S-9S. PubMed ID: 14734494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
    Miller WR
    Endocr Relat Cancer; 1999 Jun; 6(2):187-95. PubMed ID: 10731108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic observations in MCF-7 aromatase xenografts.
    Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
    Brodie A; Jelovac D; Long BJ
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
    Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
    Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
    Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.